The company’s target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. The company’s founders have designed and studied truncated tissue factor (tTF) with a C- terminal GNGRAHA peptide (tTF-NGR) binding to CD13 and causing tumor vascular thrombosis with subsequent tumor infarction.
The company is currently carrying out a Phase II/III study for patients with soft tissue sarcoma. Since tTF-NGR targets the tumor vasculature, which is similar in different tumor types, the principle of entrapping tumor therapeutics by tTF-NGR induced vascular occlusion, if successful in the active trial, may be be generalized as a treatment modality for multiple vascularized tumor entities.
In addition to the clinical lead structure tTF-NGR, the company has active preclinical programs on other targeted proteins and nucleic acids.
Subscribe for alerts on new companies featured on Startups.Bio
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …